{"protocolSection": {"identificationModule": {"nctId": "NCT02181816", "orgStudyIdInfo": {"id": "212-011"}, "secondaryIdInfos": [{"id": "JapicCTI-142592", "type": "REGISTRY", "domain": "JapicCTI"}], "organization": {"fullName": "Takeda", "class": "INDUSTRY"}, "briefTitle": "Azilsartan/Amlodipine Combination Tablets LD & HD Specified Drug-use Survey \"Long-term Use Survey\"", "officialTitle": "Azilsartan/Amlodipine (Zacras) Combination Tablets LD & HD Specified Drug-use Survey \"Long-term Use Survey\""}, "statusModule": {"statusVerifiedDate": "2019-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-06-26", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-01-31", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-01-31", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-07-02", "studyFirstSubmitQcDate": "2014-07-02", "studyFirstPostDateStruct": {"date": "2014-07-04", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-08-24", "resultsFirstSubmitQcDate": "2019-02-26", "resultsFirstPostDateStruct": {"date": "2019-06-03", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-02-26", "lastUpdatePostDateStruct": {"date": "2019-06-03", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Takeda", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this survey is to evaluate the safety and efficacy of long-term use of azilsartan/amlodipine combination tablets Low Dose (LD) \\& High Dose (HD) (Zacras Combination Tablets LD \\& HD) in hypertensive patients in daily medical practice.", "detailedDescription": "This survey was designed to evaluate the safety and efficacy of long-term use of azilsartan/amlodipine combination tablets LD \\& HD (Zacras Combination Tablets LD \\& HD) in hypertensive patients in daily medical practice.\n\nFor adults, one azilsartan/amlodipine combination tablet (20 mg/2.5 mg \\[for LD tablets\\] or 20 mg/5 mg \\[for HD tablets\\] of azilsartan/amlodipine) is administered orally once daily. Azilsartan/amlodipine combination tablets should not be used as the first-line drug for the treatment of hypertension."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Pharmacological therapy"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 1090, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Azilsartan/Amlodipine", "description": "Azilsartan/Amlodipine combination tablets (20 mg/2.5 mg or 20 mg/5 mg), orally, once daily for up to 12 months. Participants will receive interventions as part of routine medical care.", "interventionNames": ["Drug: Azilsartan/Amlodipine"]}], "interventions": [{"type": "DRUG", "name": "Azilsartan/Amlodipine", "description": "Azilsartan/Amlodipine combination tablets LD \\& HD", "armGroupLabels": ["Azilsartan/Amlodipine"], "otherNames": ["Zacras Combination Tablets LD & HD"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Participants Who Had One or More Adverse Events", "timeFrame": "Up to Month 12"}], "secondaryOutcomes": [{"measure": "Systolic Office Blood Pressure", "description": "Systolic office blood pressure level at baseline, Month 1, and the final assessment point (up to Month 12) were reported.", "timeFrame": "Baseline, Month 1, and final assessment point (up to Month 12)"}, {"measure": "Diastolic Office Blood Pressure", "description": "Diastolic office blood pressure level at baseline, Month 1, and the final assessment point (up to Month 12) were reported.", "timeFrame": "Baseline, Month 1, and final assessment point (up to Month 12)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n-Hypertensive patients\n\nExclusion Criteria:\n\n-Hypertensive patients who meet any of the following conditions, \\[1\\] to \\[3\\], are excluded from the survey:\n\n1. Patients with a history of hypersensitivity to any of the ingredients of azilsartan/amlodipine combination tablets or other dihydropyridine drugs\n2. Patients who are pregnant or having possibilities of being pregnant\n3. Diabetic patients taking aliskiren fumarate (excluding those with markedly poor blood pressure control even after other antihypertensive treatment)", "healthyVolunteers": false, "sex": "ALL", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"], "studyPopulation": "Hypertension", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Study Director", "affiliation": "Takeda", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "Osaka", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"city": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants with a historical diagnosis of hypertension were enrolled. Participants received interventions as part of routine medical care.", "recruitmentDetails": "Participants took part in the study at 271 investigative sites in Japan, from 26 June 2014 to 31 January 2017.", "groups": [{"id": "FG000", "title": "Azilsartan/Amlodipine", "description": "Azilsartan/Amlodipine combination tablets (20 mg/2.5 mg or 20 mg/5 mg), orally, once daily for up to 12 months. Participants received interventions as part of routine medical care."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "1090"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1031"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "59"}]}], "dropWithdraws": [{"type": "Case Report Forms Uncollected", "reasons": [{"groupId": "FG000", "numSubjects": "38"}]}, {"type": "Protocol Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "21"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Safety Analysis Set; The safety analysis set was defined as all participants who completed the study.", "groups": [{"id": "BG000", "title": "Azilsartan/Amlodipine", "description": "Azilsartan/Amlodipine combination tablets (20 mg/2.5 mg or 20 mg/5 mg), orally, once daily for up to 12 months. Participants received interventions as part of routine medical care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1031"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1031"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "68.5", "spread": "12.92"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1031"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "482"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "549"}]}]}]}, {"title": "Race and Ethnicity Not Collected", "populationDescription": "Race and Ethnicity were not collected from any participant.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Japan", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1031"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1031"}]}]}]}, {"title": "Duration of Diagnosis of Hypertension", "description": "Mean duration between start of study and first time of diagnosis of hypertension was reported.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1031"}]}], "categories": [{"title": "< 1 Year", "measurements": [{"groupId": "BG000", "value": "167"}]}, {"title": ">= 1 Year and < 3 Years", "measurements": [{"groupId": "BG000", "value": "126"}]}, {"title": ">= 3 Years and < 5 Years", "measurements": [{"groupId": "BG000", "value": "63"}]}, {"title": ">= 5 Years", "measurements": [{"groupId": "BG000", "value": "312"}]}, {"title": "Unknown", "measurements": [{"groupId": "BG000", "value": "363"}]}]}]}, {"title": "Healthcare Category", "description": "Participants were categorized as outpatient and inpatient.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1031"}]}], "categories": [{"title": "Outpatient", "measurements": [{"groupId": "BG000", "value": "1027"}]}, {"title": "Inpatient", "measurements": [{"groupId": "BG000", "value": "4"}]}]}]}, {"title": "Predisposition to Hypersensitivity", "description": "The baseline characteristic was analyzed in participants who had a liability or tendency to suffer from hypersensitivity.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1031"}]}], "categories": [{"title": "Had No Predisposition to Hypersensitivity", "measurements": [{"groupId": "BG000", "value": "909"}]}, {"title": "Had Predisposition to Hypersensitivity", "measurements": [{"groupId": "BG000", "value": "58"}]}, {"title": "Unknown", "measurements": [{"groupId": "BG000", "value": "64"}]}]}]}, {"title": "Medical Complications", "description": "Complications defined as a disease or a health condition for each participant at the start of study. Complications were classified as congenital anomalies, endocrine disorders, hematologic disorders, psychiatric and nervous system disorders, cardiovascular disorders, respiratory disorders, gastrointestinal (GI) disorders, renal disease and other complications. Other complications included all complications except for those mentioned above.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1031"}]}], "categories": [{"title": "Had No Medical Complications", "measurements": [{"groupId": "BG000", "value": "245"}]}, {"title": "Had Medical Complications", "measurements": [{"groupId": "BG000", "value": "786"}]}]}]}, {"title": "Medical History", "description": "Medical history defined as a disease or a health condition for each participant before start of the study. Medical history was classified as congenital anomalies, hematologic disorders, psychiatric and nervous system disorders, cardiovascular disorders, respiratory disorders, GI disorders, hepatic and biliary disorders, renal disease and other medical history. Other medical history included all medical history except for those mentioned above.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1031"}]}], "categories": [{"title": "Had No Medical History", "measurements": [{"groupId": "BG000", "value": "790"}]}, {"title": "Had Medical History", "measurements": [{"groupId": "BG000", "value": "164"}]}, {"title": "Unknown", "measurements": [{"groupId": "BG000", "value": "77"}]}]}]}, {"title": "Weight", "populationDescription": "The number analyzed is the number of participants with data available for analysis.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Kilograms (kg)", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "759"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "63.10", "spread": "14.601"}]}]}]}, {"title": "BMI", "description": "Body Mass Index = weight (kg)/\\[height(m)\\^2\\]", "populationDescription": "The number analyzed is the number of participants with data available for analysis.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/meter (m)^2", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "709"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "24.92", "spread": "4.652"}]}]}]}, {"title": "Estimate Glomerular Filtration Rate (eGFR)", "populationDescription": "The number analyzed is the number of participants with data available for analysis.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "milliliter (mL)/Minute (min)/1.73m^2", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "647"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "69.0", "spread": "19.64"}]}]}]}, {"title": "Smoking Classification", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1031"}]}], "categories": [{"title": "Never Smoked", "measurements": [{"groupId": "BG000", "value": "489"}]}, {"title": "Current Smoker", "measurements": [{"groupId": "BG000", "value": "132"}]}, {"title": "Ex-Smoker", "measurements": [{"groupId": "BG000", "value": "195"}]}, {"title": "Unknown", "measurements": [{"groupId": "BG000", "value": "215"}]}]}]}, {"title": "Drinking Habit", "description": "Participants who answered Yes or No for a question \"Drink Alcohol Almost Every Day?\" were reported.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1031"}]}], "categories": [{"title": "Yes", "measurements": [{"groupId": "BG000", "value": "272"}]}, {"title": "No", "measurements": [{"groupId": "BG000", "value": "556"}]}, {"title": "Unknown", "measurements": [{"groupId": "BG000", "value": "203"}]}]}]}, {"title": "Breast-Feeding", "populationDescription": "This baseline characteristic was analyzed only in female participants.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "482"}]}], "categories": [{"title": "Not Nursing", "measurements": [{"groupId": "BG000", "value": "479"}]}, {"title": "Unknown", "measurements": [{"groupId": "BG000", "value": "3"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Participants Who Had One or More Adverse Events", "populationDescription": "Safety Analysis Set; The safety analysis set was defined as all participants who completed the study.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Up to Month 12", "groups": [{"id": "OG000", "title": "Azilsartan/Amlodipine", "description": "Azilsartan/Amlodipine combination tablets (20 mg/2.5 mg or 20 mg/5 mg), orally, once daily for up to 12 months. Participants received interventions as part of routine medical care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1031"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.34"}]}]}]}, {"type": "SECONDARY", "title": "Systolic Office Blood Pressure", "description": "Systolic office blood pressure level at baseline, Month 1, and the final assessment point (up to Month 12) were reported.", "populationDescription": "The efficacy assessment population was defined as participants who completed the study and had available efficacy data at baseline and post baseline. The number analyzed is the number of participants with data available for analysis at the given time-point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Millimeter of Mercury (mmHg)", "timeFrame": "Baseline, Month 1, and final assessment point (up to Month 12)", "groups": [{"id": "OG000", "title": "Azilsartan/Amlodipine", "description": "Azilsartan/Amlodipine combination tablets (20 mg/2.5 mg or 20 mg/5 mg), orally, once daily for up to 12 months. Participants received interventions as part of routine medical care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1031"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1008"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "149.5", "spread": "19.13"}]}]}, {"title": "Month 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "833"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "137.2", "spread": "14.69"}]}]}, {"title": "Final Assessment Point", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1008"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "133.0", "spread": "14.14"}]}]}]}, {"type": "SECONDARY", "title": "Diastolic Office Blood Pressure", "description": "Diastolic office blood pressure level at baseline, Month 1, and the final assessment point (up to Month 12) were reported.", "populationDescription": "The efficacy assessment population was defined as participants who completed the study and had available efficacy data at baseline and post baseline. The number analyzed is the number of participants with data available for analysis at the given time-point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, Month 1, and final assessment point (up to Month 12)", "groups": [{"id": "OG000", "title": "Azilsartan/Amlodipine", "description": "Azilsartan/Amlodipine combination tablets (20 mg/2.5 mg or 20 mg/5 mg), orally, once daily for up to 12 months. Participants received interventions as part of routine medical care."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1031"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1008"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "83.3", "spread": "13.64"}]}]}, {"title": "Month 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "833"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "77.4", "spread": "11.35"}]}]}, {"title": "Final Assessment Point", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1008"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "75.0", "spread": "10.88"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0.5", "timeFrame": "Up to Month 12", "description": "At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.", "eventGroups": [{"id": "EG000", "title": "Azilsartan/Amlodipine", "description": "Azilsartan/Amlodipine combination tablets (20 mg/2.5 mg or 20 mg/5 mg), orally, once daily for up to 12 months. Participants received interventions as part of routine medical care.", "deathsNumAffected": 6, "deathsNumAtRisk": 1031, "seriousNumAffected": 16, "seriousNumAtRisk": 1031, "otherNumAffected": 15, "otherNumAtRisk": 1031}], "seriousEvents": [{"term": "Peritonitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Ver.20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1031}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Ver.20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1031}]}, {"term": "Bile duct cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Ver.20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1031}]}, {"term": "Plasma cell myeloma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Ver.20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1031}]}, {"term": "Renal cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Ver.20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1031}]}, {"term": "Brain stem haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Ver.20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1031}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Ver.20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1031}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Ver.20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1031}]}, {"term": "Prinzmetal angina", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Ver.20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1031}]}, {"term": "Sinus node dysfunction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Ver.20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1031}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Ver.20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1031}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA Ver.20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1031}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA Ver.20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1031}]}, {"term": "Spinal column stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Ver.20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1031}]}, {"term": "Renal disorder", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Ver.20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1031}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Ver.20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "The reasons of events are not determined because assessment findings were insufficient to specify the reason.", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1031}]}, {"term": "Sudden death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Ver.20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "The reasons of events are not determined because assessment findings were insufficient to specify the reason.", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1031}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Ver.20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1031}]}, {"term": "Spinal compression fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Ver.20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1031}]}], "otherEvents": [{"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Ver.20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 1031}]}, {"term": "Blood creatinine increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Ver.20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 1031}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property."}, "pointOfContact": {"title": "Medical Director", "organization": "Takeda", "email": "trialdisclosures@takeda.com", "phone": "+1-877-825-3327"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2017-06-02", "uploadDate": "2019-02-26T03:06", "filename": "Prot_000.pdf", "size": 1285194}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2017-11-29", "uploadDate": "2019-02-26T03:06", "filename": "SAP_001.pdf", "size": 1499726}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "C000557413", "term": "Azilsartan medoxomil"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M256876", "name": "Azilsartan medoxomil", "asFound": "NIV", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}